122 related articles for article (PubMed ID: 37386884)
1. Discovery of NAFLD-Improving Agents by Promoting the Degradation of Keap1.
Qi M; Zhong H; Cheng Z; Chen S; Xiao H; Shang J; Chen L; Sun J
J Med Chem; 2023 Jul; 66(13):9184-9200. PubMed ID: 37386884
[TBL] [Abstract][Full Text] [Related]
2. Development of KEAP1-targeting PROTAC and its antioxidant properties: In vitro and in vivo.
Park SY; Gurung R; Hwang JH; Kang JH; Jung HJ; Zeb A; Hwang JI; Park SJ; Maeng HJ; Shin D; Oh SH
Redox Biol; 2023 Aug; 64():102783. PubMed ID: 37348157
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
4. Aescin can alleviate NAFLD through Keap1-Nrf2 by activating antioxidant and autophagy.
Yu H; Yan S; Jin M; Wei Y; Zhao L; Cheng J; Ding L; Feng H
Phytomedicine; 2023 May; 113():154746. PubMed ID: 36905866
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.
Lee DH; Han DH; Nam KT; Park JS; Kim SH; Lee M; Kim G; Min BS; Cha BS; Lee YS; Sung SH; Jeong H; Ji HW; Lee MJ; Lee JS; Lee HY; Chun Y; Kim J; Komatsu M; Lee YH; Bae SH
Free Radic Biol Med; 2016 Oct; 99():520-532. PubMed ID: 27634173
[TBL] [Abstract][Full Text] [Related]
6. Physalin B ameliorates nonalcoholic steatohepatitis by stimulating autophagy and NRF2 activation mediated improvement in oxidative stress.
Zhang MH; Li J; Zhu XY; Zhang YQ; Ye ST; Leng YR; Yang T; Zhang H; Kong LY
Free Radic Biol Med; 2021 Feb; 164():1-12. PubMed ID: 33388433
[TBL] [Abstract][Full Text] [Related]
7. Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1-Nrf2-Dependent Manner.
Sano A; Kakazu E; Hamada S; Inoue J; Ninomiya M; Iwata T; Tsuruoka M; Sato K; Masamune A
Hepatology; 2021 Sep; 74(3):1271-1286. PubMed ID: 33724516
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway.
Hosseini H; Teimouri M; Shabani M; Koushki M; Babaei Khorzoughi R; Namvarjah F; Izadi P; Meshkani R
Int J Biochem Cell Biol; 2020 Feb; 119():105667. PubMed ID: 31838177
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2.
Bathish B; Robertson H; Dillon JF; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2022 Aug; 188():221-261. PubMed ID: 35728768
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Anti-Oxidative Stress Response Improves Metabolic Changes in L-Selectin-Deficient Mice but Does Not Prevent NAFLD Progression or Fecal Microbiota Shifts.
Eswaran S; Babbar A; Drescher HK; Hitch TCA; Clavel T; Muschaweck M; Ritz T; Kroy DC; Trautwein C; Wagner N; Schippers A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298930
[TBL] [Abstract][Full Text] [Related]
11. 2,3,5,4'-tetrahydroxystilbence-2-O-β-D-glucoside attenuates hepatic steatosis via IKKβ/NF-κB and Keap1-Nrf2 pathways in larval zebrafish.
Wang C; Hu NH; Yu LY; Gong LH; Dai XY; Peng C; Li YX
Biomed Pharmacother; 2020 Jul; 127():110138. PubMed ID: 32387861
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GCN2 alleviates hepatic steatosis and oxidative stress in obese mice: Involvement of NRF2 regulation.
Yuan J; Yu Z; Gao J; Luo K; Shen X; Cui B; Lu Z
Redox Biol; 2022 Feb; 49():102224. PubMed ID: 34954499
[TBL] [Abstract][Full Text] [Related]
13. Design and characterization of a heterobifunctional degrader of KEAP1.
Chen H; Nguyen NH; Magtoto CM; Cobbold SA; Bidgood GM; Meza Guzman LG; Richardson LW; Corbin J; Au AE; Lechtenberg BC; Feltham R; Sutherland KD; Grohmann C; Nicholson SE; Sleebs BE
Redox Biol; 2023 Feb; 59():102552. PubMed ID: 36473314
[TBL] [Abstract][Full Text] [Related]
14. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis.
Gao G; Xie Z; Li EW; Yuan Y; Fu Y; Wang P; Zhang X; Qiao Y; Xu J; Hölscher C; Wang H; Zhang Z
J Nat Med; 2021 Jun; 75(3):540-552. PubMed ID: 33590347
[TBL] [Abstract][Full Text] [Related]
15. Nomilin and its analogue obacunone alleviate NASH and hepatic fibrosis in mice via enhancing antioxidant and anti-inflammation capacity.
Han Y; Luo L; Li H; Zhang L; Yan Y; Fang M; Yu J; Gao X; Liu Y; Huang C; Fan S
Biofactors; 2023; 49(6):1189-1204. PubMed ID: 37401768
[TBL] [Abstract][Full Text] [Related]
16. Hydrogen Sulfide Alleviates Liver Injury Through the S-Sulfhydrated-Kelch-Like ECH-Associated Protein 1/Nuclear Erythroid 2-Related Factor 2/Low-Density Lipoprotein Receptor-Related Protein 1 Pathway.
Zhao S; Song T; Gu Y; Zhang Y; Cao S; Miao Q; Zhang X; Chen H; Gao Y; Zhang L; Han Y; Wang H; Pu J; Xie L; Ji Y
Hepatology; 2021 Jan; 73(1):282-302. PubMed ID: 32219872
[TBL] [Abstract][Full Text] [Related]
17. Pyridostigmine attenuated high-fat-diet induced liver injury by the reduction of mitochondrial damage and oxidative stress via α7nAChR and M3AChR.
Xue R; Wu Q; Guo L; Ye D; Cao Q; Zhang M; Xian Y; Chen M; Yan K; Zheng J
J Biochem Mol Toxicol; 2024 Mar; 38(3):e23671. PubMed ID: 38454809
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte-specific Keap1 deletion reduces liver steatosis but not inflammation during non-alcoholic steatohepatitis development.
Ramadori P; Drescher H; Erschfeld S; Schumacher F; Berger C; Fragoulis A; Schenkel J; Kensler TW; Wruck CJ; Trautwein C; Kroy DC; Streetz KL
Free Radic Biol Med; 2016 Feb; 91():114-26. PubMed ID: 26698665
[TBL] [Abstract][Full Text] [Related]
19. Flavonoids from Scutellaria amoena C. H. Wright alleviate mitochondrial dysfunction and regulate oxidative stress via Keap1/Nrf2/HO-1 axis in rats with high-fat diet-induced nonalcoholic steatohepatitis.
Fang QL; Qiao X; Yin XQ; Zeng YC; Du CH; Xue YM; Zhao XJ; Hu CY; Huang F; Lin YP
Biomed Pharmacother; 2023 Feb; 158():114160. PubMed ID: 36571996
[TBL] [Abstract][Full Text] [Related]
20.
Xiao L; Xiong H; Deng Z; Peng X; Cheng K; Zhang H; Jiang L; Sun Y
Food Funct; 2023 Jan; 14(1):500-515. PubMed ID: 36519687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
